Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Cerus Corporation
  6. Summary
    CERS   US1570851014

CERUS CORPORATION

(CERS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/23/2021 11/24/2021 11/26/2021 11/29/2021 11/30/2021 Date
7.11(c) 7.17(c) 6.98(c) 6.93(c) 6.89 Last
1 614 945 941 750 820 356 1 270 899 1 361 513 Volume
-0.14% +0.84% -2.65% -0.72% -0.58% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 134 M - -
Net income 2021 -58,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -20,0x
Yield 2021 -
Sales 2022 160 M - -
Net income 2022 -52,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -22,6x
Yield 2022 -
Capitalization 1 187 M 1 187 M -
Capi. / Sales 2021 8,85x
Capi. / Sales 2022 7,43x
Nbr of Employees 266
Free-Float 97,3%
More Financials
Company
Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components... 
Sector
Medical Equipment, Supplies & Distribution
Calendar
12/03 | 02:00pmPresentation
More about the company
Ratings of Cerus Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CERUS CORPORATION
11/19Cerus Corporation to Participate in Stephens Annual Investment Conference
BU
11/08Cerus Corporation to Participate in Stifel 2021 Virtual Healthcare Conference
BU
11/08INSIDER SELL : Cerus
MT
11/02CERUS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
11/02Cerus Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
11/02CERUS : Q3 Earnings Snapshot
AQ
11/02Cerus Q3 Loss Narrows as Revenue Rises; Full-Year Product Revenue Outlook Raised; Share..
MT
11/02Cerus Corporation Announces Record Third Quarter 2021 Financial Results and Raises Full..
PU
11/02Cerus Corporation Announces Record Third Quarter 2021 Financial Results and Raises Full..
BU
11/02Earnings Flash (CERS) CERUS CORPORATION Reports Q3 Revenue $42.1M, vs. Street Est of $3..
MT
11/02Cerus Corporation Raises Product Revenue Guidance for the Year 2021
CI
10/19CERUS CORPORATION : to Release Third Quarter 2021 Financial Results on November 2, 2021
BU
10/01CERUS CORPORATION : Applauds FDA Requirements Effective Today to Safeguard the U.S. Platel..
BU
09/20CERUS CORPORATION : Announces INTERCEPT Fibrinogen Complex Customer Presentations at SABM ..
BU
09/15CERUS CORPORATION : to Present at the 2021 Cantor Global Virtual Healthcare Conference
BU
More news
News in other languages on CERUS CORPORATION
11/08VENTE D'INITIÉS : Cerus
11/02Cerus réduit sa perte au troisième trimestre et augmente son chiffre d'affaires ; révis..
11/02Earnings Flash (CERS) CERUS CORPORATION annonce un chiffre d'affaires de 42,1 millions ..
11/02Cerus Corporation revoit à la hausse ses prévisions de revenus de produits pour l'année..
2007CERUS CORP : Cerus annonce avoir passé un accord portant sur la fourniture du système sang..
More news
Chart CERUS CORPORATION
Duration : Period :
Cerus Corporation Technical Analysis Chart | CERS | US1570851014 | MarketScreener
Technical analysis trends CERUS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 6,89 $
Average target price 10,20 $
Spread / Average Target 48,0%
EPS Revisions
Managers and Directors
William Mariner Greenman President, Chief Executive Officer & Director
Kevin Dennis Green Chief Financial Officer & Vice President-Finance
Daniel N. Swisher Chairman
Laurence M. Corash Chief Scientific Officer
Carol M. Moore Senior VP-Regulatory Affairs, Quality & Clinical
Sector and Competitors